A-01 Registration at the conference venue Tuesday 14:00-18:30 |
A-02 Opening ceremony and welcome reception Tuesday 19:30 |
B-01 Registration at the conference venue Wednesday 08:00-09:00 |
B-02 Welcome and Introduction Wednesday 09:00-09:15 |
B-03 Steven Kern Conducting clinical trials in challenging environments Wednesday 09:15-09:30 |
B-04 France Mentré Estimating an effective dose for a repurposed drug to treat Ebola: the case of favipiravir Wednesday 09:30-09:55 |
B-05 Matthias Machacek Estimating an effective dose for a new drug to treat Ebola with incomplete information: the case of Zmapp Wednesday 09:55-10:20 |
B-06 Scott Berry An Adaptive Platform Trial for Ebola: Application to Future Epidemics Wednesday 10:20-10:45 |
B-07 Coffee break, poster and software session I: posters in Group I (with poster numbers starting with I-) are accompanied by their presenter Wednesday 10:45-12:15 |
B-08 Roberto Bizzotto A model of glucose clearance to improve the description of glucose homeostasis Wednesday 12:15-12:35 |
B-09 Rada Savic A Longitudinal HbA1c Model Elucidates Genes Linked to Disease Progression on Metformin Therapy Wednesday 12:35-12:55 |
B-10 Lunch Wednesday 12:55-14:25 |
B-11 David Giltinan On the 20th anniversary of 'Nonlinear models for repeated measurement data': why write a book about PK/PD modeling? Wednesday 14:25-14:50 |
B-12 Marie Davidian On the 20th anniversary of 'Nonlinear models for repeated measurement data': Nonlinear mixed effects modeling 20 years later Wednesday 14:50-15:15 |
B-13 Tea break, poster and software session II: posters in Group II (with poster numbers starting with II-) are accompanied by their presenter Wednesday 15:15-16:40 |
B-14 José David Gómez-Mantilla Towards Patient Stratification and Treatment in the Autoimmune Disease Lupus Erythematosus using a Systems Pharmacology approach. Wednesday 16:40-17:00 |
B-15 Gopichand Gottipati Modeling of a composite score in Parkinson’s Disease using Item Response Theory Wednesday 17:00-17:20 |
B-16 Emilie Hénin Determination of effective blood concentrations of cyclosporine in pediatric severe aplastic anemia based on a time-to-response model Wednesday 17:20-17:40 |
C-01 Huixin Yu Development of a tumour growth inhibition model to elucidate the effect of ritonavir on intratumoural metabolism and anti-tumour effect of docetaxel in a mouse model for hereditary breast cancer Thursday 09:00-09:25 |
C-02 - - Automated proper lumping for simplification of systems models Thursday 09:25-09:50 |
C-03 Adrien Tessier Modelling pharmacogenetic data in population studies during drug development Thursday 09:50-10:15 |
C-04 Presentation of Lewis Sheiner student session awards Thursday 10.15-10.20 |
C-05 Coffee break, poster and software session III: posters in Group III (with poster numbers starting with III-) are accompanied by their presenter Thursday 10:20-11:45 |
C-06 Michael Betancourt Part I: Building Robust PK/PD Population Models with Bayesian Inference Thursday 11:45-12:30 |
C-07 Sebastian Weber Part II: Building Robust PK/PD Population Models with Bayesian Inference Thursday 11:45-12:30 |
C-08 Thierry Wendling Application of a Bayesian population approach to physiologically-based modelling and simulation of mavoglurant pharmacokinetics Thursday 12:30-12:50 |
C-09 Lunch Thursday 12:50-14:10 |
C-10 Rong Deng Towards Model-Based Drug Development of New Therapeutics for Hepatitis C Virus Thursday 14:10-14:30 |
C-11 Joe Standing Treating Resistant Gram-Negatives: Bedside to Bench and Back Thursday 14:30-14:50 |
C-12 Anders Kristoffersson A Pharmacokinetic-Pharmacodynamic (PKPD) Model Characterizing Resistance for Predictions of Bacterial Kill in vivo Thursday 14:50-15:10 |
C-13 Nick Holford Announcement of WCoP 2016 Thursday 15:10-15:15 |
C-14 Tea break, poster and software session IV: posters in Group IV (with poster numbers starting with IV-) are accompanied by their presenter Thursday 15:15-16:30 |
C-15 Andrew Hooker Preconditioning of Nonlinear Mixed Effect models for Stabilization of the Covariance Matrix Computation Thursday 16:30-16:50 |
C-16 Eric Strömberg Simulated model based adaptive optimal design of adult to children bridging study using FDA stopping criteria. Thursday 16:50-17:10 |
C-17 Sebastian Ueckert Alternative to Resampling Methods in Maximum Likelihood Estimation for NLMEMs by Borrowing from Bayesian Methodology Thursday 17:10-17:30 |
D-01 Joel Tarning Semi-mechanistic time-to-event modelling in malaria Friday 09:15-09:35 |
D-02 Natalie Filmann Modeling the PK/PD of hepatitis B immunoglobulin after hepatitis B induced liver transplantation by an extended Target Mediated Drug Disposition Model Friday 09:35-09:55 |
D-03 Dimitra Bon Multiscale modelling for hepatitis C treatment Friday 09:55-10:15 |
D-04 Preview of PAGE2016 Friday 10.15-10.25 |
D-05 Coffee break Friday 10:25-10:55 |
D-06 Nadia Terranova Analysis of individual target lesions for tumor size models of drug resistance: a new methodology encompassing signal processing and machine learning Friday 10:55-11:15 |
D-07 Nelleke Snelder PKPD modelling of the relationship between testosterone and PSA in patients with prostate cancer during treatment with leuprorelin – What is the optimal testosterone level? Friday 11:15-11:35 |
D-08 Anna Georgieva Kondic Model-based analysis of the relationship between pembrolizumab exposure and efficacy in patients with melanoma and NSCLC: across indication comparison Friday 11:35-11:55 |
D-09 Pauline Mazzocco Modeling the emergence of resistance in low-grade glioma patients treated with temozolomide, and simulations using a stochastic approach Friday 11:55-12:15 |
D-10 Closing remarks Friday 12.15-12.25 |
D-11 Audience input for potential PAGE2015 topics Friday 12:25-12:45 |